Is apolipoprotein E required for cognitive function in humans? Implications for alzheimer drug development

JAMA Neurology

Volumn 71, Issue 10, 2014, Pages 1213-1215

  Lane Donovan, Courtney ^a   Herz, Joachim ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E ANTIBODY; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; CHOLESTEROL; IMMUNOMODULATING AGENT; LIPOPROTEIN; UNCLASSIFIED DRUG; LIPH PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 2; TRIACYLGLYCEROL LIPASE;

ALZHEIMER DISEASE; APOE GENE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; COGNITION; EDITORIAL; GENETIC RISK; HETEROZYGOTE; HUMAN; LOSS OF FUNCTION MUTATION; NONHUMAN; PASSIVE IMMUNIZATION; VIRAL GENE DELIVERY SYSTEM; XANTHOMATOSIS; GENETICS; HYPERLIPOPROTEINEMIA TYPE 3; MALE;

APOLIPOPROTEINS E; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; LIPASE; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS;

EID: 84907996982     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.2013     Document Type: Editorial

References (26)

1. Corder EH, Saunders AM, StrittmatterWJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123): 921-923.
2. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet. 1994;7 (2): 180-184.
3. Mak ACY, Pullinger CR, Tang LF, et al. Effects of the absence of apolipoprotein E on lipoproteins, neurocognitive function, and retinal function [published online August 11, 2014]. JAMA Neurol. doi: 10.1001/jamaneurol.2014.2011.
4. Björkhem I, Lütjohann D, Diczfalusy U, Ståhle L, Ahlborg G,Wahren J. Cholesterol homeostasis in human brain. J Lipid Res. 1998;39(8): 1594-1600.
5. Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta. 1987;917(1): 148-161.
6. Schaefer EJ, Gregg RE, Ghiselli G, et al. Familial apolipoprotein E deficiency. J Clin Invest. 1986;78 (5): 1206-1219.
7. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258(5081): 468-471.
8. Gordon I, Grauer E, Genis I, Sehayek E, Michaelson DM. Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci Lett. 1995;199(1): 1-4.
9. Masliah E, Mallory M, Ge N, Alford M, Veinbergs I, Roses AD. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp Neurol. 1995;136(2): 107-122.
10. Masliah E, SamuelW, Veinbergs I, Mallory M, ManteM, Saitoh T. Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Res. 1997;751(2): 307-314.
11. Anderson R, Barnes JC, Bliss TV, et al. Behavioural, physiological and morphological analysis of a line of apolipoprotein E knockout mouse. Neuroscience. 1998;85(1): 93-110.
12. Moghadasian MH, McManus BM, Nguyen LB, et al. Pathophysiology of apolipoprotein E deficiency inmice. FASEB J. 2001;15(14): 2623-2630.
13. Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nat Rev Immunol. 2013;13(12): 875-887.
14. Spires-Jones TL, Hyman BT. The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron. 2014;82(4): 756-771.
15. Mawuenyega KG, SigurdsonW, Ovod V, et al. Decreased clearance of CNS beta-Amyloid in Alzheimer's disease. Science. 2010;330(6012): 1774.
16. Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med. 2011;3 (89): 89ra57.
17. Sanan DA,Weisgraber KH, Russell SJ, et al. Apolipoprotein E associates with beta amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest. 1994;94(2): 860-869.
18. Dean DC III, Jerskey BA, Chen K, et al. Brain differences in infants at differential genetic risk for late-onset Alzheimer disease. JAMA Neurol. 2014;71 (1): 11-22.
19. Bales KR, Liu F,Wu S, et al. Human APOE isoform-dependent effects on brain beta-Amyloid levels in PDAPP transgenicmice. J Neurosci. 2009; 29(21): 6771-6779.
20. Hudry E, Dashkoff J, Roe AD, et al. Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain. Sci Transl Med. 2013;5 (212): Ra161.
21. Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 1997;17(3): 263-264.
22. Kim J, Jiang H, Park S, et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J Neurosci. 2011;31(49): 18007-18012.
23. Cramer PE, Cirrito JR,Wesson DW, et al. ApoE-directed therapeutics rapidly clear β-Amyloid and reverse deficits in AD mouse models. Science. 2012;335(6075): 1503-1506.
24. Donkin JJ, Stukas S, Hirsch-Reinshagen V, et al. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1mice. J Biol Chem. 2010;285 (44): 34144-34154.
25. Liao F, Hori Y, Hudry E, et al. Anti-ApoE antibody given after plaque onset decreases Aβ accumulation and improves brain function in a mouse model of Aβ amyloidosis. J Neurosci. 2014; 34(21): 7281-7292.
26. Anstey KJ, Lipnicki DM, Low LF. Cholesterol as a risk factor for dementia and cognitive decline. Am J Geriatr Psychiatry. 2008;16(5): 343-354.